There is no assessment of the reporting quality of antifungal randomized, controlled trials (RCT), upon which guidelines for the treatment of invasive aspergillosis (IA) in patients with hematological malignancy are based. Trial reports were identified through Trip, Cochrane, Medline, and Embase database searches. Report quality was assessed using the 25-item CONSORT checklist and a rating scale of 1 (strongly disagree) to 4 (strongly agree). The primary endpoint was quality as assessed by mean group-scores among papers published at the time of the most recent IA treatment guidelines. Seven RCTs were identified for analysis. Overall mean group-score for all seven papers was 2.44 (out of a total of four). There were significant differences between publications regarding overall reporting quality (P < .001) and specifically for the Methods and Results (P = .004 and P = .010, respectively), which best reflect data quality. The Cornely trial report achieved the highest mean group-score overall (3.15 ± 0.93; 95% CI, 2.82, 3.47), as well as for Methods (3.36) and Results (3.40). Mean group scores also showed that it was of significantly higher overall quality than the other six publications (P-value range; .012 to <.001), and of higher quality for Methods than five publications (P-value range; .013 to <.001). Incorporating this CONSORT analysis into the evidence-based grading systems in North American (IDSA), European (ECIL and ESCMID) IA guidelines could alter the value placed on these RCTs, thereby impacting on clinical recommendations.
Introduction
Invasive aspergillosis (IA) has emerged as an important cause of morbidity and mortality in immunocompromised hosts, 1 including recipients of haematopoietic stem-cell transplantation (HSCT) and solid organ transplantation, patients with advanced human immunodeficiency virus (HIV) infection and inherited immunodeficiency, and those with prolonged neutropenia. 2 IA is associated with unacceptably high mortality. 3 Early diagnosis is associated with improved patient survival but is rarely achieved with current methods. 4 The lack of definitive diagnostic criteria has also complicated studies of the treatment of IA and few randomized controlled trials (RCTs) have been published. 2 While RCTs are the most rigorous way of determining whether a cause-effect relation exists between treatment and outcome, and for assessing the cost effectiveness of a treatment, 5 studies with inadequate methodology are associated with bias, especially exaggerated treatment effects. 6 In light of overwhelming evidence of poor-quality reporting of RCTs, an international group of clinical trialists, statisticians, epidemiologists, and journal editors, methodologists developed and published the CONsolidated Standards Of Reporting Trials (CONSORT) Statement in 1996. 7 The
CONSORT Statement is an evidence-based, minimum set of recommendations for writing RCT reports, which aims to facilitate their complete and transparent reporting and, thus, their critical appraisal and interpretation. The current version published in 2010 consists of a 25-item checklist of the key items that should be included in an RCT report, with the items grouped according to the general format of a journal publication; namely, Title and Abstract, Methods, Results, Discussion, and Other Information such as funding. 8 However, since many of the 25 items are subdivided into two categories, the checklist actually comprises 37 items. Furthermore, most of the 37 items consist of multiple statements that require independent evaluation. The CONSORT Statement is currently endorsed by 585 journals, 9 and a recent systematic review shows that while most RCTs published in these journals are still incompletely reported, the CONSORT Statement beneficially influences their reporting quality. 10 Although numerous publications have used the CON-SORT statement to evaluate the quality of reports of RCTs in various subspecialities of medicine, to our knowledge no publication has evaluated the quality of RCTs focusing on the treatment of IA. Since current guidelines for the treatment of IA are based on a paucity of RCT data, we considered that a critique of the published clinical data according to CONSORT was warranted. The CONSORT tool published in 2010 was used for this purpose, regardless of the study's year of publication, as the aim of the analysis was to assess the quality of reporting of data that are used to inform current treatment guidelines and, hence, influence clinical practice.
Materials and methods
Data sources, search strategies, and studies selection Trip, Cochrane, Medline, and Embase searches were conducted in March 2016 for reports on RCTs involving patients with proven or probable invasive aspergillosis. The following filters and search criteria were used: "randomised/randomized controlled trial," "proven or probable invasive aspergillosis," "proven or probable invasive mould/mold infection," "acute leukaemia/leukemia," "haematopoietic/hematopoietic stem-cell transplantation," and "myelodysplastic syndrome." The searches were limited to English language articles from 1976 to present and did not include conference abstracts. Identification of reports for inclusion in the study was also based on the authors' knowledge, and a review of references cited in the current aspergillosis treatment guidelines of the Infectious Diseases Society of America (IDSA), European Conference on Infections in Leukemia (ECIL), and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID). 2, 11, 12 Reporting assessment tools
The quality of reporting was evaluated according to the main CONSORT 2010 checklist and accompanying Explanation and Elaboration guidelines, 8 except for the abstract, which was evaluated according to the Extended CONSORT Statement for Reporting RCTs in Journal and Conference Abstracts. 13 The extent to which each item fulfilled the CONSORT requirements was assessed using the four-point rating scale associated with the Appraisal of Guidelines for Research and Evaluation (AGREE) I Instrument, which ranges from 1 "Strongly Disagree" to 4 "Strongly Agree" (Table 1) . 14 Following its publication in 2003, the AGREE I Instrument quickly became the international gold standard Table 1 . AGREE instrument rating scale used to assess whether the RCT reports fulfilled the CONSORT checklist.
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Rating scale Definition
1: Strongly Disagree
Assessor is confident that the item has not been fulfilled at all or no information is available 2: Disagree Assessor is unsure whether the item has been fulfilled; 3: Agree with 'Agree' or 'Disagree' being used depending on the extent to which the issue has been addressed.
4: Strongly Agree
Assessor is confident that the item has been fully met for evaluating the quality of reporting of practice guidelines (http://www.agreetrust.org).
Methodological evaluation
The four authors independently assessed all the RCT publications. For Item 17b, which relates to presentation of both absolute and relative effect sizes for binary outcomes, a statistician was consulted to aid interpretation of the CON-SORT Explanation and Elaboration guidelines. Following collation of the individual results, the authors met to agree a group-score for each of the 37 CONSORT items. In situations where all the individual scores were positive (scores 3 and 4), the predominant score was assigned; if the scores were equally balanced between 3 and 4, then the lower score was assigned. Similar principles were applied if all the individual scores were negative (scores 1 and 2). In situations where the individual scores were a mixture of positive and negative scores, each author provided evidence to support his/her chosen score, and a group score was agreed for each item. This discussion identified several difficulties associated with interpreting the CON-SORT requirements and, thus, assigning a score. The authors therefore developed a set of "scoring principles." Individual scores for all 37 items were checked against these principles and modified where appropriate, and the previously agreed group score was also modified if required. The "scoring principles" were as follows:
r For information that was given in the publication but not in the section designated by CONSORT, an individual score was reduced by one point.
r "Not applicable" (NA) was used when it was clear from the information provided that the CONSORT item was not applicable.
r "Not stated/not applicable" (NS/NA) was used when it was not possible from the information provided to explicitly determine if the CONSORT item was applicable, but the authors considered it reasonable to assume that it was not applicable, that is, the information would have been provided if relevant. This principle was applied to the following items: -Item 3b: "Important changes to methods after trial commencement (such as eligibility criteria), with reasons" -Item 6b: "Any changes to trial outcomes after the trial commenced, with reasons" -Item 14b: "Why the trial ended or was stopped"
Endpoints and statistical analysis
The primary study endpoint consisted of the quality of publications (overall and according to each section within CONSORT) as assessed by mean group scores. The overall and by-section quality of the publications as assessed according to the proportion of group scores for which there was a positive result (scores 3 and 4) was a secondary endpoint. For all analyses, greater emphasis was placed on results obtained for the Methods and Results sections within the CONSORT checklist since these sections address data quality.
The Mann-Whitney U test, which is an extension of the Mann-Whitney U test to three or more groups, was used to compare the publication found to be of the highest quality based on primary and secondary endpoint mean group scores with the other publications included in the analysis.
Since the aim of the study was to assess the quality of reporting of data that are used to inform current treatment guidelines, the primary and secondary endpoints, as well as the comparison of the highest quality paper with the other papers, were based on those publications that had been published prior to May 2014, the date upon which the most recent guidelines (ESCMID) were made available.
Results
Eligible studies
The Trip, Cochrane, Medline, and Embase searches identified a total of seven publications that met the study inclusion criteria, one of which was excluded because it was published after the date of the most recent current treatment guidelines. Two additional qualifying publications were known by the authors, but one of these was also excluded due to its date of publication. A review of the current IDSA, ECIL, and ESCMID aspergillosis treatment guidelines identified no further publications for inclusion in the analysis. Consequently, the study included a total of seven publications ( Fig. 1 ). All papers were published in peer-reviewed journals, with six of the journals specializing in infectious diseases, cancer, or hematology (Table 2 ).
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Primary and secondary outcomes
The group scores for each of the 37 items within the CONSORT checklist according to the publication are shown in Table S1 (available at http://www.mmy. oxfordjournals.org/). The overall and by-section quality of the publications based on mean group scores (primary endpoint) and the proportion of group scores for which there was a positive result (secondary endpoint) are summarised in Tables 3 and 4, respectively. In general, the quality of reporting was markedly below that required by CONSORT. Out of a possible score of 4 for each item, the mean group score for all seven papers Note: Publications were identified according to the following criteria: "randomised/randomized controlled trial" , "proven or probable invasive aspergillosis" , "proven or probable invasive mould/mold infection" , "acute leukaemia/leukemia" , "haematopoietic/hematopoietic stem-cell transplantation" , "myelodysplastic syndrome" , English language, and published from 1976 to present. Conference abstracts were excluded. 1 -4) 2.36(1 -4) 2.43(1 -4) 2.08(1 -4) 2.38(1 -4) 1.83(1 -4) 1.45(1 -3 Corresponding results for the proportion of positive groupscores (3 or 4) were 54.2%, 48.5%, and 67.2%. Statistical analyses of the primary and secondary endpoint data showed that there were significant differences between the seven publications in terms of the overall quality of reporting (P < .001 and P < .002, respectively), as well as the quality of reporting of Methods (P = .004 and P = .007, respectively) and Results (P = .010 and P = .010, respectively). Primary endpoint data showed that the Cornely publication was of the highest quality in terms of the overall mean group score (3.15 ± 0.93; 95% CI, 2.82, 3.47), and mean group scores for Methods (3.36) and Results (3.40). Verweij ranked lowest in terms of mean group scores overall (1.73 ± 0.87; 95% CI, 1.41, 2.06), for Methods (1.45) and Results (1.78). The remaining five papers (Bowden, Herbrecht, Ellis, Leenders, and Caillot) were tightly grouped with overall scores ranging from 2.35 to 2.53, and those for Methods and Results ranging from 1.83 to 2.43 and 2.67 to 3.22, respectively. Assessment according to the proportion of positive scores also showed that Cornely ranked highest overall (82.4%; 95% CI, 65.5, 93.2) and for Methods (92.9%). It rated second highest for Results (90%), with Herbrecht scoring the highest for this section (100%). The publication by Verweij had the lowest proportion of positive scores overall (26.7%, 95% CI, 12.3, 45.9), for Meth- Comparison between the Cornely report and the six other publications showed that it was of significantly higher quality overall and for Methods as assessed by mean group scores (Table 5) . Similar results were seen for secondary endpoint data except for the comparison between the Cornely and Leenders reports, which just failed to reach statistical significance (92.9% vs 61.5%; P = .055). Primary and secondary endpoint data showed that the Cornely report was also of significantly higher quality than the Verweij publication for Results and of comparable quality to the five other publications.
Discussion
Primary and secondary endpoint data revealed significant differences in the quality of reporting between the seven publications, overall and for the CONSORT subsections addressing Methods and Results. The Cornely publication achieved the highest mean group scores (overall, Methods, and Results) and the highest proportion of positive scores (overall and Methods). The Herbrecht publication scored the highest for the proportion of positive scores for Results. Conversely, the quality of the Verweij publication was rated as being lower than the other publications.
A key reason for performing this analysis was to critique the RCT reports from a clinical perspective. The Herbrecht study showed that voriconazole was associated with better survival, improved responses, and fewer severe drug-related adverse events than deoxycholate amphotericin B (D-AMB). 19 Liposomal amphotericin B (L-AMB) is recommended as alternative therapy to voriconazole 2, 11, 12 based on the results of the study by Cornely, which compared two doses of L-AMB in the primary treatment of IA. 17 The IDSA grading system for ranking recommendations classes both the Herbrecht and Cornely studies as AI, with A (the strength of recommendation) defined as "Good evidence to support the recommendation for use" and I (quality of the evidence) defined as "Evidence from ≥1 properly randomised, controlled trial".
ECIL and ES-
CMID also grades the Herbrecht study as AI, with A defined as "Good evidence to support a recommendation for use" and "Strongly support a recommendation for use," respectively, and I defined as "Evidence from at least one properly randomized, controlled trial" and "Evidence from at least 1 properly designed randomized controlled trial (orientated on the primary endpoint of the trial," 11, 12 However, ECIL 12 Conversely, our study showed that the Cornely report was of higher quality overall and for Methods than that by Herbrecht. This finding suggests that a more rigorous assessment of published reports, such as this CONSORT analysis, can provide further useful evaluation of the quality of papers over and above the commonly used grading system for ranking recommendations that are solely based on trial design and the magnitude of reported outcomes. Two of the publications identified in our database searches, Maertens et al. 2015 22 and Marr et al. 2015, 23 were published after the current IDSA, ECIL, and ES-CMID guidelines were produced. Both publications reported on prospective, double-blind, multicenter studies that evaluated voriconazole in the primary treatment of IA or other invasive mould disease; the Maertens study comparing voriconazole with isavuconazole, 22 and the Marr study comparing voriconazole monotherapy with voriconazole plus anidulafungin. 23 The Maertens study received financial support from Astellas and Basilea, and the Marr study from Pfizer. Isaconazole was shown to be noninferior to voriconazole in terms of survival and associated with fewer study-drug-related adverse events. 22 Voriconazole plus anidulafungin failed to show superiority in 6-week survival compared with voriconazole monotherapy and was associated with more treatment-emergent hepatobiliary adverse events. 23 Our assessment of the publications according to mean group scores (primary endpoint) provided a more accurate reflection of their reporting quality compared with assessment according to the proportion of positive results (secondary endpoint). For example, primary endpoint data showed that the quality of reporting of Results was higher for the Cornely publication than the Herbrecht publication (3.40 vs 3.22). Conversely, secondary endpoint data showed that a positive score (score 3 or 4) was achieved for nine of the 10 (90%) assessable items in the Cornely report and all of the nine (100%) assessable items in the Herbrecht report. However, closer inspection of the secondary endpoint data revealed that a score of 4 (item fully reported) was achieved for only two of the subitems in the Herbrecht paper compared with five subitems in the Cornely paper.
The difference in quality between the reports included in our study and the supplementary analysis may be partly due to their year of publication. The report by Verweij, which was assessed as being of the poorest quality, was published two years before release of the first CONSORT Statement in 1996 and its adoption by peer-reviewed journals. The other reports were all published after the 1996 CONSORT Statement, with the years of publication ranging from 1998 to 2007 in our study and 1998 to 2015 in our supplementary analysis. Our study assessed the quality of reporting using the latest 2010 CONSORT Statement, when it may have been more appropriate to use the 1996 or 2001 CONSORT Statements that were applicable at the time the reports were published. 7, 24 Indeed, some CONSORT analyses have analyzed quality of reporting using the CONSORT Statement relevant to the given article's year of publication and have excluded articles before 1996. 25 However, we believe it is appropriate to use the most recent CONSORT tool as we are assessing the quality of reporting of available RCTs that are used to inform the latest clinical guidelines.
As noted by authors of other CONSORT analyses, a problem in using the CONSORT checklist is that each of the items listed consists of multiple statements, each of which can be evaluated independently. 26 This presents difficulties if a "pass/failure" method is used to determine whether an item fulfils all the CONSORT Statement requirements. If all components within an item must be fulfilled to certify it as a "pass," then an article that complied with none of the components would be equated with one that complied with all but one. 26 To address this issue, we assessed each item using the four-point rating scale associated with the AGREE I Instrument published in 2003. 14 However, the specificity afforded by the four-point scale remained problematic for items with a high number of components. Assessment us-ing the seven-point rating scale (1-strongly disagree to 7-strongly agree) associated with the latest version of AGREE (AGREE II) may have proven valuable in this study. 27 An alternative method for quantitative use of CONSORT, which has been adopted in other CONSORT analyses, has been to divide each CONSORT item into subitems. 26, 28, 29 As described by other authors, we encountered many problems of logic, validity, and interpretability relating to the CONSORT requirements and developed a set of "scoring principles" to enhance the consistency of our individual scores. 26 Some of these problems related to the way in which an item was worded. For example, Item 6b states, "Any changes to trial outcomes after the trial commenced, with reasons." We decided that it was reasonable to assume the item was nonapplicable if no mention of changes to the trial were mentioned in the report; not stated/not applicable (NS/NA) was assigned in such a situation. Changing the wording of Item 6b to, "Where there were changes to trial outcomes after the trial started, were reasons given?", would aid its interpretation and assessment.
Whether an article has fulfilled all the CONSORT requirements may also be influenced by the word count imposed by some journals. Abstracts are often limited to 250 to 300 words, making it difficult to include all the information required by the Extended CONSORT Statement for Reporting RCTs in Journal and Conference Abstracts. Restrictions to an article's total word count may also result in loss of important detail, especially the introductory section. 26 In summary, this is the first application of CONSORT analysis to RCTs for treatment of IA. As with previous CONSORT work, a number of issues of methodology and interpretation were identified, which should be addressed in future iterations of CONSORT. In an attempt to standardise the assessment of CONSORT items and improve objectivity between authors, a rating scale was used. This approach showed significant quality differences between the seven RCTs analyzed, with the Cornely report being of the highest quality and the Verweij report being rated least well compared with the other studies. It is reasonable to place greater value on data from well-designed, statistically robust, and well-reported studies as evaluated by CON-SORT. However, exactly how this value is apportioned remains unresolved. The limitations of CONSORT must also be considered: for example, two studies may score similarly in CONSORT even if one shows markedly better outcomes than the other, as CONSORT does not evaluate the magnitude of reported outcomes. Given these inconsistencies, does the CONSORT statement have any clinical relevance? Should the evidence grading used by American (IDSA) or European (ECIL and ESCMID) IA treatment guidelines include an assessment of quality of reporting according to the CONSORT statement? If so, it seems likely that an impact on clinical recommendations would follow.
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